Key result
Periprocedural LMWH bridging provides a management option for patients on long-term warfarin undergoing surgery.
Why the study?
There is little consensus on appropriate perioperative management of patients on long-term warfarin therapy requiring interruption for surgical or invasive procedures.
Does periprocedural bridging with low-molecular-weight heparins balance the risks of bleeding and thromboembolism in patients on extended warfarin therapy undergoing surgical procedures?
Does periprocedural bridging with low-molecular-weight heparins balance the risks of bleeding and thromboembolism in patients on extended warfarin therapy undergoing surgical procedures?
This review provides a rationale for using low-molecular-weight heparins for periprocedural bridging in patients on long-term warfarin therapy, emphasizing individualized risk-benefit assessment.
No takes yet. Share an insight, caveat, or question.
May inform individualized bridging decisions in warfarin patients; leaves open RCT confirmation of net benefit.
Jafri et al. (2004) conducted a review in Patients on extended warfarin therapy requiring periprocedural management. Periprocedural bridging with low-molecular-weight heparins (LMWHs) was evaluated. Periprocedural bridging with low-molecular-weight heparins (LMWHs) provides a management option for patients on long-term warfarin therapy undergoing surgical procedures.